Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

Recruiting Phase 2 Interventional Study
Alcohol Use Disorder
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
19 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
36 (estimated)
Sponsor
Centre for Addiction and Mental Health · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Meets DSM-5 criteria for AUD. * Meets drinking criteria of average weekly consumption \> 10 standard drinks for women and \> 15 standard drinks for men over the past 90 days. * Willing to take study medication and participate in laboratory sessions requiring self-administratio…
Contacts

Kelly Xiao, MSc

416-535-8501

kelly.xiao@camh.ca

CONTACT